The DOI matches its Crossref record.
Hepatic Histological Findings in Suspected Drug-Induced Liver Injury: Systematic Evaluation and Clinical Associations
Abstract
Drug-induced liver injury (DILI) is considered to be a diagnosis of exclusion. Liver biopsy may contribute to diagnostic accuracy, but the histological features of DILI and their relationship to biochemical parameters and outcomes are not well defined. We have classified the pathological pattern of liver injury and systematically evaluated histological changes in liver biopsies obtained from 249 patients with suspected DILI enrolled in the prospective, observational study conducted by the Drug Induced Liver Injury Network. Histological features were analyzed for their frequency within different clinical phenotypes of liver injury and to identify associations between clinical and laboratory findings and histological features. The most common histological patterns were acute (21%) and chronic hepatitis (14%), acute (9%) and chronic cholestasis (10%), and cholestatic hepatitis (29%). Liver histology from 128 patients presenting with hepatocellular injury had more severe inflammation, necrosis, and apoptosis and more frequently demonstrated lobular disarray, rosette formation, and hemorrhage than those with cholestasis. Conversely, histology of the 73 patients with cholestatic injury more often demonstrated bile plugs and duct paucity. Severe or fatal hepatic injury in 46 patients was associated with higher degrees of necrosis, fibrosis stage, microvesicular steatosis, and ductular reaction among other findings, whereas eosinophils and granulomas were found more often in those with milder injury. Conclusion : We describe an approach for evaluating liver histology in DILI and demonstrate numerous associations between pathological findings and clinical presentations that may serve as a foundation for future studies correlating DILI pathology with its causality and outcome. (Hepatology 2014;59:661–670)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Studies comparing DILI with AIH have included DILI cases more broadly and have not focused on the comparison between AIH and DI-ALH.
“Thus far, studies comparing DILI with AIH have included DILI cases more broadly and have not focused on the comparison between AIH and DI-ALH.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 16
- Fontana, 2010, Standardization of nomenclature and causality assessment in druginduced liver injury: summary of a clinical research workshop., Hepatology, 52, 730, 10.1002/hep.23696 · DOI
- Ostapowicz, 2002, Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States., Ann Intern Med, 137, 947, 10.7326/0003-4819-137-12-200212170-00007 · DOI · Paper page
- Lee, 2005, Recognizing druginduced liver injury: current problems, possible solutions., Toxicol Pathol, 33, 155, 10.1080/01926230590522356 · DOI
- Shapiro, 2007, Causality assessment of druginduced hepatotoxicity: promises and pitfalls., Clin Liver Dis, 11, 477, 10.1016/j.cld.2007.06.003 · DOI
- Kleiner, 2009, The pathology of druginduced liver injury., Semin Liver Dis, 29, 364, 10.1055/s-0029-1240005 · DOI
- Ramachandran, 2009, Histological patterns in druginduced liver disease., J Clin Pathol, 62, 481, 10.1136/jcp.2008.058248 · DOI
- Fontana, 2009, DrugInduced Liver Injury Network (DILIN) prospective study: rationale, design and conduct., Drug Saf, 32, 55, 10.2165/00002018-200932010-00005 · DOI · Paper page
- Kleiner, 2007, Relationship of biochemical to histologic findings and the pathological pattern of injury among cases identified in the NIH DrugInduced Liver Injury Network (DILIN) Study., Gastroenterology, 132, A773
- Danan, 1993, Causality assessment of adverse reactions to drugsI. A novel method based on the conclusions of international consensus meetings: application to druginduced liver injuries., J Clin Epidemiol, 46, 1323, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
- Ishak, 1995, Histological grading and staging of chronic hepatitis., J Hepatol, 22, 696, 10.1016/0168-8278(95)80226-6 · DOI
- Katoonizadeh, 2006, Liver regeneration in acute severe liver impairment: a clinicopathological correlation study., Liver Int, 26, 1225, 10.1111/j.1478-3231.2006.01377.x · DOI
- Bjornsson, 2007, The impact of eosinophilia and hepatic necrosis on prognosis in patients with druginduced liver injury., Aliment Pharmacol Ther, 25, 1411, 10.1111/j.1365-2036.2007.03330.x · DOI
- Babany, 1986, Chronic liver disease after low daily doses of amiodarone. Report of three cases., J Hepatol, 3, 228, 10.1016/S0168-8278(86)80031-9 · DOI
- Holmberg, 1980, Adverse reactions to nitrofurantoin. Analysis of 921 reports., Am J Med, 69, 733, 10.1016/0002-9343(80)90443-X · DOI
- Iwarson, 1979, Nitrofurantoininduced chronic liver disease. Clinical course and outcome of five cases., Scand J Gastroenterol, 14, 497
- Suzuki, 2011, The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus druginduced liver injury., Hepatology, 54, 931, 10.1002/hep.24481 · DOI · Paper page
Cited by
Sorted by citations
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study
Chalasani, N., Bonkovsky, H. L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., Reddy, K. R., Watkins, P. B., Navarro, V., Barnhart, H., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.006 · Cited by 925
Self-citationAndrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Self-citationACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.131 · Cited by 860
Self-citationDrug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652
Self-citationACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Chalasani, N. P., Maddur, H., Russo, M. W., Wong, R. J., Reddy, K. R., & on behalf of the Practice Parameters Committee of the American College of Gastroenterology (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001259 · Cited by 430
Self-citationAASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Self-citationDrug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S. M., Hamid, S., Tan, S. S., Philips, C. A., George, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10144-3 · Cited by 181
Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., Terziroli Beretta-Piccoli, B., Schramm, C., Kleiner, D. E., De Martin, E., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.033 · Cited by 166
Self-citationSundaram, V., & Björnsson, E. S. (2017) · Hepatology Communications · doi:10.1002/hep4.1088 · Cited by 138
Chakraborty, M., Fullerton, A. M., Semple, K., Chea, L. S., Proctor, W. R., Bourdi, M., Kleiner, D. E., Zeng, X., Ryan, P. M., Dagur, P. K., et al. (2015) · Hepatology · doi:10.1002/hep.27764 · Cited by 64
Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Mao, Y., Ma, S., Liu, C., Liu, X., Su, M., Li, D., Li, Y., Chen, G., Chen, J., Chen, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10633-7 · Cited by 62
Mechanisms of idiosyncratic drug-induced liver injury
Uetrecht, J. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2018.12.001 · Cited by 49
Validation of the revised electronic version of RUCAM for diagnosis of DILI in Chinese patients
Zhao, X., Wang, Y., Lai, R., Wang, X., Yu, Y., Li, M., Zhao, H., Ma, Z., Li, M., Guo, T., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000235 · Cited by 12
What have we learned from animal models of idiosyncratic, drug-induced liver injury?
Roth, R. A., & Ganey, P. E. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1760246 · Cited by 8
Liu, Y., Zhan, S.-P., Song, L., Chen, Y., Jia, Y.-T., Liu, F., Sun, F.-J., Wang, Q., & Xia, P.-Y. (2020) · Medical Science Monitor · doi:10.12659/msm.919435 · Cited by 6
Xiong, Y.-T., Wang, J.-F., Li, L., Bai, Z.-F., Liu, Y., Huang, A., Wang, K.-X., Fu, Y., Yang, W., Guo, C., et al. (2024) · iLIVER · doi:10.1016/j.iliver.2024.100095 · Cited by 6
The contemporary epidemiology, causes, and management of drug-induced liver injury
Swanson, L., & Fontana, R. J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001011
Self-citationDILI Differences and Similarities between the US and Europe
Toro-Ortiz, J. P., Andrade, R. J., & Pinazo-Bandera, J. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00733-x
Metadata
- Authors
- Kleiner, D. E., Chalasani, N. P., Lee, W. M., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Hayashi, P. H., Davern, T. J., Navarro, V., Reddy, R., Talwalkar, J. A., Stolz, A., Gu, J., Barnhart, H., & Hoofnagle, J. H.
- Venue
- Hepatology
- Published
- 2014-02
- Volume
- 59
- Issue
- 2
- Pages
- 661-670
- ISSN
- 0270-9139
- PMC
- PMC3946736
- Cited by
- 396
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
